"Exploiting Cancer's Tactics: Enhanced T Cell Therapies Melt Tumors"

A study in mice has shown that engineered CAR-T cells carrying a mutation found in cancerous T cells can effectively eliminate tumors that do not respond to current CAR-T therapies. The mutation, known as CARD11–PIK3R3, enhances the T-cell function and enables them to infiltrate tumors and exhibit long-lasting cancer-killing activity. The supercharged cells were able to melt away tumors in mice with both blood and solid cancers, and the researchers hope to move these cells towards clinical trials in the next two to three years. This approach opens the door for better CAR-T therapies in the future and provides an opportunity to discover other cancer mutations that can enhance T-cell therapies.